Browse our archive of webinars on pharmaceutical and biomedical research from collaborations between pharmaceutical companies, government, biotechnology companies and academia to create new drug discovery opportunities.
NanoMIPs, often called “plastic antibodies”, are made using a proprietary self-assembly process where the template molecule is incubated with monomers, each of which is free in so...
This talk reviews the advances in the field of Proteolysis Targeting Chimeras (PROTACs). It is divided to five topics: (1) Ligand-induced Target Protein Destabilization; (2) Small-Molecule L...
Antibody-based therapeutics are helping patients across a wide range of disease areas, from cancer, such as Rituximab treatment of CD20-positive non-Hodgkin's lymphomas, to infectious di...
The field of melanoma has been transformed by the parallel development of effective immune and targeted therapies. There is now strong evidence of cross-talk between oncogenic signaling...
Whether you are performing killing assays, immunophenotyping of TILs, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery...
Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and...
There are many tumor biomarkers but, they mostly reflect tumor mass or past growth, when what is more important is to obtain an indication of future growth and therapy response.Proliferat...
G-protein coupled receptors (GPCRs) represent the single largest class of druggable targets in the human genome. Of the 390 or so druggable and non-olfactory human GPCRs there exist many whic...
Centhaquine (previously used names, centhaquin and PMZ-2010; International Non-proprietary Name (INN) recently approved by WHO is centhaquine) is being developed by us as a first-in-class re...
Princess Margaret Living Biobank (PMLB) is a repository for patient-derived organoid models. PMLB has generated over200 organoid models from lung, pancreas, colon, ovary, esophageal and brea...
High-throughput sequencing technology such as RNASeq and whole genome sequencing has enabled deep characterization of health and disease states. Biomarker discovery by these means has only h...
Cellular research is optimal when using physiologically-relevant cell phenotypes and genotypes of human origin. This assertion has accelerated the adoption of primary cells, stem cells, and i...
Rapid, accurate estimation of relative ligand affinities offers the potential to allow computational methods to direct drug design and development. Towards this goal we have developed t...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...
Preterm birth (PTB) is the leading cause of infant mortality and morbidity worldwide. Both preterm labor and neonatal injuries have been linked to inflammation. Of all mediators of inflammati...
Stable cell lines are critical tools of cellular assays in drug discovery and development. Over-expressing cell lines are needed to screen for hits, while functional cell lines are needed fo...
Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the Methyl CpG Binding Protein 2 (MECP2) gene. In mouse models of RTT, deficits in long-term potentiation (LTP) at...
Whether you are performing killing assays, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery of new therapeutics. Conc...
The liver plays a critical role in the metabolism and clearance of more than 70% of marketed drugs. Furthermore, toxicity to the liver is a major reason for preclinical and clinical drug fai...
The quest for alternatives to animal safety testing has fueled the development, characterization, and validation of many new technologies. There have been advances in cell and tissue models...
One-third of FDA-approved drugs target G protein-coupled receptors (GPCRs), transmembrane cell surface proteins that recognize small molecules and polypeptides with diverse chemical scaffolds...
The continued evolution of precision medicine from the early successes seen in Oncology to other areas of medicine, in particular, Chronic Disease Management, is dependent on the efficient t...
Recent advances in DNA sequencing and omics-based capabilities are revealing incredible therapeutic opportunities and quickly transforming drug discovery. Molecularly targeted drugs aim to e...
The use of primary cells in vitro is compromised by the limited quantity of cells that can be isolated from one donor, a lack of or very restricted proliferation capacity (e.g. hepatocytes)...
Structure based drug design is now well established as a highly efficient approach in pharmaceutical research. The approach uses atomic level detail structures of target proteins, most...
The last two decades have seen an explosion in the volume of oncology data generated using next-generation sequencing (NGS) and multi-omics techniques. As a result, there is a growing need fo...
Over the past 25 years surgically dependent animal models have expanded from a small, almost niche area in pharmaceutical research to an important component of most research portfolios. In t...
NanoMIPs, often called “plastic antibodies”, are made using a proprietary self-assembly process where the template molecule is incubated with monomers, each of which is free in so...
